Sustainability | February 22, 2022
AstraZeneca partners with Honeywell to develop next-gen respiratory inhalers
New inhalers would have near-zero Global Warming Potential propellant
New inhalers would have near-zero Global Warming Potential propellant
The investment in Indian clinical technology expertise in Hyderabad comes amid the clinical trials sector's move towards decentralised trials
The COVID-19 pandemic has triggered the rapid growth of the biotherapeutics market
Essential products manufactured by Sartorius, using Sü dpack polymer films made from Dow resins, support safe and effective vaccine production for global vaccine supply
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
Phase 2a clinical proof-of-concept biomarker study for PXL065 in ALD now anticipated to start midyear
Tepmetko is the first and only oral MET inhibitor to be approved in the European Economic Area for treating adult patients with advanced NSCLC harboring alterations leading to METex14 skipping, who require systemic therapy following prior treatment
Launching Dexamethasone, Azacitidine, Carboprost, and Atropine for the Institutional Market
Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study
The focus should be on streamlining regulations, developing new molecules, increased industry academia collaboration and tapping the potential of traditional medicines
Subscribe To Our Newsletter & Stay Updated
